Liposomal Doxorubicin Market To Reach $1.89 Billion By 2030

Liposomal Doxorubicin Market Growth & Trends

The global liposomal doxorubicin market size is expected to reach USD 1.89 billion by 2030, registering a CAGR of 6.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of various pipeline products awaiting approval by the U.S. FDA and European Medicines Agency is one of the key attributes of this market. The first liposomal doxorubicin formulation was launched in 1995, namely Doxil/Caelyx by Janssen Products and LP & Myocet by Teva Pharmaceutical Laboratories. Doxil, the brand name of liposomal doxorubicin, is under development, and post its commercialization, the product is expected to create significant value over the next 3 to 4 years.

The increasing U.S. FDA approval for drug production is also anticipated to boost the market. The increasing indication of these drugs for various conditions such as AIDS-related Kaposi sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand. The technological advancements in the drugs formulations to overcome the adverse effects on health and also introduction of various types of medication delivery systems, such as coated nanoparticles, are some of the pivotal factors impelling the demand for the drug.

Liposomal doxorubicin is primarily approved for the treatment of myeloma, Kaposi sarcoma, and ovarian cancer. However, due to its wide usage in other conditions as well, in 2015, breast cancer accounted for the maximum revenue of 21.2%. The increasing prevalence of breast cancer is leading to growing demand for chemotherapy treatment, which accounts for the majority of revenue share. Besides breast carcinoma, ovarian cancer, multiple myeloma, and liver cancer also held a significant share in 2015. The use of doxorubicin for liver carcinoma treatment is rapidly growing, and this application is expected to grow with the fastest CAGR of 7.8% over the forecast period.

 Request a free sample copy or view report summary: Liposomal Doxorubicin Market Report

Liposomal Doxorubicin Market Report Highlights

• The increasing number of mergers & acquisitions and partnerships for clinical trials on technologically advanced doxorubicin formulations will boost market growth

• Increasing investment in Asia Pacific pertaining to the R&D, improving healthcare infrastructure, and heightened patient cognizance regarding targeted cancer therapies and chemotherapy will drive regional market growth

• The lipodox segment dominated the market with 40.0% share in 2023 and is expected to grow at a CAGR of 7.3% from 2024 to 2030.

Liposomal Doxorubicin Market Segmentation

Grand View Research has segmented the global liposomal doxorubicin market based on product, application, distribution channel and region:

Liposomal Doxorubicin Product Outlook (Revenue, USD Million, 2018 - 2030)

• Doxil/Caelyx

• Lipodox

• Myocet

• Others

Liposomal Doxorubicin Application Outlook (Revenue, USD Million, 2018 - 2030)

• Breast Cancer

• Ovarian Cancer

• AIDS-related Kaposi’s Sarcoma

• Multiple Myeloma

• Other Solid Tumors

Liposomal Doxorubicin Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Retail Pharmacies

• Online Pharmacies

Liposomal Doxorubicin Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players Liposomal Doxorubicin Market

• Sun Pharmaceutical Industries Ltd.

• Johnson & Johnson Services, Inc.

• Merck & Co., Inc.

• Cipla

• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

• Lupin

• Cadila Pharmaceuticals

• SRS Life Sciences

• GSK plc

• Pfizer Inc.

• Sanofi

• Sigma-Aldrich Co.